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Cholera toxin (CT) is composed of a monomeric 
A subunit (CTA) and a pentameric B subunit 
(CTB). After binding of CTB to cell surface gan­
gliosides, CTA acts to catalyze the ADP ribo­
sylation  of  the  intracellular  G  protein  subunit 
Gs, which then dissociates from Gs­dimer 
and activates adenylate cyclase. This results in the 
induction of cAMP and activation of cAMP­
dependent protein kinase A. Enzymatically active 
CT, as well as other ligands that induce cAMP 
production, can inhibit the production of IL­12 
from monocytes and DCs (1, 2). CT also inhibits 
expression of IL­121 and ­122 receptors on 
activated T cells, suppresses the function of Th1 
but not Th2 T cell clones (3), and drives the dif­
ferentiation of Th2 and IL­10–producing Tr1 
T cells in vitro (4). In vivo, CT inhibits the 
production of both IL­12 and IFN­ in mice 
given LPS systemically (5). Given orally with 
most soluble protein antigens, CT preferentially 
drives Th2 responses locally and systemically, 
which is associated with production of IgA and 
IgG1>IgG2a antibodies; and after repeated oral 
dosing, CT induces high IgE levels to coad­
ministered antigens that results in anaphylaxis to 
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Prior studies have demonstrated that cholera toxin (CT) and other cAMP-inducing factors 
inhibit interleukin (IL)-12 production from monocytes and dendritic cells (DCs). We show 
that CT inhibits Th1 responses in vivo in mice infected with Toxoplasma gondii. This  
correlated with low serum IL-12 levels and a selective reduction in the numbers of CD8+ 
conventional DCs (cDCs) in lymphoid organs. CT inhibited the function of interferon (IFN) 
regulatory factor (IRF) 8, a transcription factor known to positively regulate IL-12p35 and 
p40 gene expression, and the differentiation of CD8+ and plasmacytoid DCs (pDCs). 
Fluorescence recovery after photobleaching analysis showed that exposure to CT, forskolin, 
or dibutyryl (db) cAMP blocked LPS and IFN-–induced IRF8 binding to chromatin.  
Moreover, CT and dbcAMP inhibited the binding of IRF8 to the IFN-stimulated response 
element (ISRE)–like element in the mouse IL-12p40 promoter, likely by blocking the  
formation of ISRE-binding IRF1–IRF8 heterocomplexes. Furthermore, CT inhibited the 
differentiation of pDCs from fms-like tyrosine kinase 3 ligand–treated bone marrow cells in 
vitro. Therefore, because IRF8 is essential for IL-12 production and the differentiation of 
CD8+ cDCs and pDCs, these data suggest that CT and other Gs-protein agonists can affect 
IL-12 production and DC differentiation via a common mechanism involving IRF8.
© 2009 la Sala et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.jem.org/misc/terms.shtml). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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CT to block IL­12 production and responsiveness likely con­
tributes to its ability to drive Th2 responses when given orally 
with protein antigens (1).
Although it has been reported that CTB alone can down­
regulate IL­12 expression (7), its inhibitory potency is a frac­
tion of that caused by CT holotoxin (5). This indicates that 
the ability of CT to suppress IL­12 production is primarily 
dependent on the enzymatically active A subunit, as is its 
ability to act as an adjuvant in vivo (1, 2). In addition, the 
suppression  of  IL­12  by  ligand­mediated  activation  of  Gs 
protein–coupled receptors, such as those for prostaglandin 
E2, histamine, 2­adrenergic agonists, adenosine, cannabi­
noids, and opiates, as well as by the cell­permeable cAMP ana­
logue dbcAMP, suggests that the direct induction of cAMP by 
Gs protein activation plays a key role in CT­mediated IL­12 
suppression (1, 2). However, the downstream effects of Gs 
protein–induced cAMP on the signaling pathways required 
for IL­12 production are not clear.
RESULTS AND DISCUSSION
Gs protein–mediated inhibition of IL-12 production by cDCs
Prior studies demonstrated the ability of CT to inhibit the pro­
duction of IL­12 from human monocytes and monocyte­derived 
DCs (5). We initially determined whether this also applied to 
freshly isolated mouse conventional DCs (cDCs), and whether it 
extended to other Gs protein agonists. CT, as well as agonists for 
2­adrenergic receptor (salbutamol), and the adenosine A2a 
receptor (CGS 21680; 2­p­[2­Carboxyethyl] phenethylamino­
5­N­ethylcarboxamidoadenosine hydrochloride) suppressed the 
production of both IL­12p40 and IL­12p70 from spleen cDCs 
stimulated with SAC and IFN­ (Fig. S1), whereas IL­10 pro­
duction was not suppressed (unpublished data).
CT inhibits the production of IL-12 after infection  
with Toxoplasma gondii in vivo
CT has been shown to induce Th2 responses after oral admin­
istration with soluble protein antigens; however, because CT 
is normally given with inactivated proteins, the extent to 
which CT can modify the helper T (Th) cell phenotype dur­
ing the induction of strong Th1 responses, as occurs after infec­
tion with intracellular pathogens, is not clear. Furthermore, 
when given intranasally, or orally with less purified antigens, 
CT has been reported to induce Th1 and Th2 responses (8, 9). 
Therefore, we decided to test the ability of CT to modify 
Th1 responses in mice during systemic infection of BALB/c 
mice with a high dose of the ME­49 strain of T. gondii. In this 
model, mice develop IL­12–dependent Th1 responses that 
clear the infection with 100% survival (10). As shown in Fig. 1, 
systemic administration of CT during the course of infection 
resulted in 100% mortality with nearly identical kinetics to that 
occurring after systemic neutralization of IL­12 (Fig. 1 A). 
In addition, parasite loads were high (Fig. 1 B) and serum 
levels of IL­12 and IFN­ were suppressed in both CT and 
anti–IL­12–treated groups (Fig. 1 C), consistent with CT 
having a dominant inhibitory effect on IL­12 production and 
the induction of Th1 responses to this infection.
subsequent antigenic challenge (6). Together with several addi­
tional effects on immune and nonimmune cells, the ability of 
Figure 1.  Reduced IL-12 and IFN- production in CT-treated mice 
results in increased parasite burden and mortality after T. gondii 
infection. (A) Survival rate of BALB/c mice infected with T. gondii. Mortal-
ity was monitored daily. Data shown were obtained from eight mice/
group and are representative of three experiments producing similar results. 
(B) Parasite burden in the peritoneum was measured 5 d after infection. 
Results are presented as mean ± SD of five mice/group and are represen-
tative of three independent experiments. (C) Serum cytokine production 
after T. gondii infection. Sera were harvested 5 d after infection. Data 
shown are given as mean ± SD of 5 individual mice and are representative 
of three experiments that produced similar results. *, P ≤ 0.002.JEM VOL. 206, June 8, 2009  1229
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showed a 20–30% reduction of total cell numbers in the 
spleen, there was a dramatic preferential reduction of CD11c+ 
CD8+ cDCs compared with CD11b+ cDCs (Fig. 2 A) and 
other lymphocyte compartments (Fig. 2 B). The loss of 
CD8+ cDCs was not caused by apoptosis (Fig. S2); was 
transient, with cell numbers returning to normal levels by day 6; 
and was dose dependent, with 5 µg of CT having maximal 
CT treatment results in a loss of CD8+ cDCs
Although it is likely that a variety of cells produce IL­12 dur­
ing infection with T. gondii in vivo, including macrophages 
(11) and neutrophils (12), CD8+ cDCs are thought to be 
one major source of this essential cytokine (13). We therefore 
asked whether CT administration affects IL­12 production 
by cDC subsets in vivo. Although mice treated with CT 
Figure 2.  CT administration induces preferential loss of splenic CD8+ cDCs without affecting other lymphocyte compartments in vivo. 
Spleen cells were isolated from BALB/c mice 48 h after i.p. CT injection and analyzed by flow cytometry. (A) MACS-enriched CD11c+ spleen cells. CD8+ 
cDCs were defined as CD11c+CD19CD8+. (B) Effect of CT on T cell (CD4+ and CD8+) and B cell (CD19+) populations. Data shown are representative of 
five experiments showing similar effects (Fig. S2).1230 CT-INDUCED INHIBITION OF IRF8 FUNCTION | la Sala et al.
the serum. Prior studies have shown that CD8+ cDCs are a 
significant source of IL­12 under these conditions (13), and 
that IFN­ production after LPS administration can be 
blocked with antibodies to IL­12p40 (5). We found that low 
doses of CT (0.5 µg) consistently suppressed both IL­12 and 
IFN­ production in response to LPS (Fig. S3). Furthermore, 
the total percentages of CD4+ and CD8+ T cells, as well as 
CD19+ B cells, were unchanged after CT treatment (Fig. 2 B). 
These studies suggest that systemic administration of CT has 
two dose­dependent effects in vivo, one resulting in the loss 
of CD8+ cDCs and the other resulting in the inhibition of 
IL­12 production by DCs and possibly other cells.
CT blocks IFN regulatory factor (IRF) 8–chromatin 
interactions
In our initial studies using human monocytes stimulated with 
LPS alone or LPS and IFN­, CT had no effect on the acti­
vation of signaling molecules positively regulating IL­12 pro­
duction, such as NF­B, STAT­1, or the mitogen­activated 
and 0.5 µg of CT having minimal effects (Fig. S3 B). More­
over, no difference in the viability of splenocytes or periph­
eral blood cells from CT­treated versus PBS­treated controls 
or CTB­treated mice was found (unpublished data). Treatment 
with CTB had no effect on CD8+ cDC numbers (unpub­
lished data), indicating that ADP ribosylate activity of CTA 
was required for the loss of CD8+ cDCs.
The loss of IL­12–producing CD8+ cDCs may con­
tribute to the effects seen with CT in T. gondii infection. To 
address this issue more directly, we infected mice after treat­
ment with 0.5 µg of CT, which has only minor effects on 
CD8+ cDC numbers. At this dose, the effects of CT on the 
course of T. gondii infection were highly variable, yet in some 
experiments we observed a significant effect on survival and 
parasite load, despite only a minor change in CD8+ cDC 
numbers (Fig. S3 and not depicted). To test the possibility 
that CT may affect IL­12 production independent of CD8+ 
cDC loss, we gave graded doses of CT to mice, administered 
LPS systemically, and measured IL­12 and IFN­ levels in 
Figure 3.  cAMP-elevating agents reduce IRF8–chromatin interaction elicited by LPS and IFN- stimulation. IRF8-deficient myeloid progenitor 
Tot2 cells were transduced with IRF8-GFP, left untreated (untreated), or treated with LPS (1 µg/ml) and IFN- (100 ng/ml) for 4 h (LPS+IFN-), and sub-
jected to FRAP analysis. Where indicated, cells were exposed to CT (20 ng/ml), CTB (20 ng/ml), forskolin (20 ng/ml), or dbcAMP (100 µM) for 1 h before LPS 
and IFN- treatment. Data shown represent the mean fluorescence obtained from at least 15 independent acquisitions from a single experiment repre-
sentative of three performed that yielded similar results. The response of cells treated with CT, CTB, or forskolin or dbcAMP alone is the same as that mea-
sured in untreated cells.JEM VOL. 206, June 8, 2009  1231
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protein kinases (MAPKs) p38 and JNK (unpublished data).   
In addition, CT had no effect on the activation of extracellular 
signal­regulated kinase MAPK, which is a known negative 
regulator of IL­12 expression (unpublished data). Moreover, 
CT treatment did not affect the surface expression of Toll­
like receptor (TLR)­4 or IFN­ receptor on LPS­stimulated 
or unstimulated monocytes (unpublished data) or the IFN­ 
receptor signaling pathway, as IFN­–induced up­regulation 
of HLA­DR and CD40 was unaffected (unpublished data).
We next focused our study on the effect of CT on the 
function of IRF8, which is a transcription factor expressed by 
DCs, macrophages, granulocytes, and B cells; it is a positive 
regulator of IL­12p35 and IL­12p40 transcription (14–17) 
and has a central role in the differentiation of CD8+ cDC and 
plasmacytoid DC (pDC) populations. Furthermore, produc­
tion of IL­12 in T. gondii infection is dependent on IRF8 (11). 
IRF8/ mice lack the CD8+ and pDCs, although they have 
CD11c+CD8 cDCs (18–21). Moreover, in these mice, the 
residual IRF8/ cDCs display impaired responsiveness to 
TLR­mediated signals and fail to produce IL­12p40 (18). 
Thus, IRF8 is essential for both IL­12 production by myeloid 
cells including cDCs and the development of CD8+ cDCs 
that likely represent an IL­12–producing DC subsets during 
T. gondii infection.
We initially studied the dynamic interaction of IRF8 
with chromatin in live cells using fluorescence recovery after 
photobleaching (FRAP) analysis, a method that was recently 
applied to the study of IRF8–chromatin interactions (22). 
For these studies, IRF8/ Tot2 cells were stably transduced 
with IRF8­GFP that localizes to the nucleus. In the nucleus, 
IRF8­GFP is present in two functionally distinct forms: a 
fraction of low­mobility IRF8 molecules engaged in interac­
tions with chromatin and a pool of highly mobile, unbound 
IRF8. As depicted in Fig. 3, in untreated IRF8­transduced 
Tot2 cells, a small fraction of immobile chromatin­bound 
IRF8 molecules was present, and 80% of the initial fluores­
cence signal is recovered within 4 s after photobleaching. 
When cells were stimulated with LPS and IFN­ that favored 
IRF8–chromatin  interaction,  an  increase  in  the  immobile 
IRF8 pool, and a consequent reduction of the highly mobile 
unbound IRF8 fraction, occurred, resulting in significantly 
slower fluorescence recovery. In these samples, only 60% of 
the recovery occurred within the first 4 s of analysis, and the 
maximal recovery achieved was 70% of initial signal com­
pared with 90% observed in untreated cells (Fig. 3, red vs. 
black line). Treatment with CT, but not CTB, before stimu­
lation with LPS and IFN­ produced a recovery curve similar 
to that of unstimulated cells (Fig. 3, B and C). Similar to what 
we observed with CT, cells pretreated with the G protein–
independent adenylate cyclase activator forskolin or the 
membrane­permeable cAMP analogue dbcAMP and stimu­
lated with LPS and IFN­ displayed a quick recovery of fluo­
rescence (Fig. 3, E and F). Importantly, treatment with CT, 
CTB, forskolin, or dbcAMP alone did not alter the kinetics 
of fluorescence recovery (Fig. 3, A and D). IRF8­GFP was 
not overexpressed in IRF8/ Tot2 cells because levels were 
Figure 4.  CT and dbcAMP reduce IRF8 binding to the ISRE-like region 
of the mouse IL-12p40 promoter and prevent IRF1–IRF8 heterocomplex 
formation. (A) Schematic representation of the 92 to +12 region of the 
mouse IL-12p40 promoter. The ISRE-like sequence is represented in bold.  
(B) CT and dbcAMP, but not CTB, inhibited IRF8, but not IRF1 or TFIIB, interac-
tion with the mouse IL-12p40 promoter. A biotinylated DNA probe correspond-
ing to the 81 to 24 region of the mouse IL-12p40 promoter encompassing 
the ISRE-like sequence, and a biotinylated mutant probe containing substitu-
tion (indicated by the lower case letters) in the context of the ISRE-like element 
were conjugated with streptavidin-bound magnetic beads and incubated with 
500 µg of nuclear extracts from RAW 264.7 cells stimulated for 4 h as indi-
cated. CT, CTB (both at 20 ng/ml), and dbcAMP (100 µM) were added 1 h before 
addition of LPS (1 µg/ml) and IFN- (100 ng/ml). Bound material was eluted, 
separated by 10% SDS-PAGE, and detected by Western blot analysis using 
rabbit anti-IRF8 antibody. (C) CT or dbcAMP did not modify the total amount of 
IRF8 or IRF1 in the nucleus. 500 µg of nuclear extracts were analyzed to mea-
sure the presence of IRF8 or IRF1 by SDS-PAGE Western blot. Membranes were 
stripped and reblotted to verify equal protein loading using an antinucleolin 
antibody. (D) CT reduces IRF1–IRF8 heterocomplex formation induced by LPS 
and IFN-. 1 mg of nuclear extract was immunoprecipitated with anti-IRF1 
antibody and analyzed by Western blot for the presence of IRF8 or IRF1.  
(E) Tyrosine phosphorylation of IRF1 is not affected by CT. 1 mg of nuclear 
extracts was immunoprecipitated with antiphosphotyrosine antibody and 
analyzed by Western blot for the presence of IRF1. Data shown are representa-
tive of at least three experiments.1232 CT-INDUCED INHIBITION OF IRF8 FUNCTION | la Sala et al.
below those of endogenous IRF8 in a macrophage cell line 
(22). Collectively, these data indicate that increased levels of 
cAMP, secondary to CT­induced Gs protein ADP ribosyl­
ation, impair the ability of IRF8 to bind to chromatin, and 
therefore to interact with its target promoters. Interestingly, 
IRF8 amplifies the transcription of its own gene (23). Thus, 
the cAMP­dependent inhibition of IRF8 binding to its own 
promotor would lead to reduced IRF8 mRNA expression, a 
concept that is consistent with prior studies showing cAMP­
dependent IRF8 mRNA down­regulation (24, 25).
CT inhibits IRF8 binding to the IL-12p40 promoter  
and its interaction with IRF1
IRF8 together with IRF1 has been reported to enhance   
IL­12p40 gene transcription induced by LPS and IFN­ by 
forming a heterocomplex that interacts with a cis­acting ele­
ment resembling the ISRE (IFN­stimulated response ele­
ment; ISRE­like) located in the IL­12p40 mouse promoter 
(15, 26). To assess if CT inhibits DNA–IRF8 interaction spe­
cifically at the level of the IL­12p40 promoter, we performed 
a DNA affinity binding assay using a biotinylated IL­12p40 
promoter sequence containing the native ISRE­like element 
conjugated to streptavidin beads (Fig. 4 A). As shown in   
Fig. 4 B, IRF8 in nuclear extracts from RAW 264.7 cells stim­
ulated with LPS and IFN­ bound to the probe­conjugated 
beads, and this binding was completely abrogated when cells 
were pretreated with CT, but not CTB. Moreover, a simi­
lar inhibitory effect was exerted by dbcAMP. Significantly 
reduced binding of IRF8 to a probe carrying a mutation in 
the ISRE­like element was observed (Fig. 4 B, lane 6) indi­
cating that IRF8 binding was dependent on the integrity of 
the ISRE­like element.
The same ISRE­like element is a consensus sequence for 
IRF1 (26), therefore we investigated the effect of CT or 
dbcAMP on the ability of IRF1 to interact with the IL­12p40 
promoter. Similar to IRF8, stimulation with LPS and IFN­ 
induced IRF1 binding; however, neither CT nor dbcAMP 
reduced such interaction. Moreover, binding of TFIIB, a com­
ponent of the RNA polymerase II complex, to the TATA box 
element included in the probe sequence, was unaffected by 
CT treatment, indicating that the inhibition exerted by CT 
and dbcAMP was specific for IRF8. Moreover, similar levels 
of IRF8 and IRF1 were detected in nuclear extracts of all 
cells stimulated with LPS and IFN­, indicating that observed 
effects were not caused by reduced IRF8 expression in the 
nucleus (Fig. 4 C).
The concomitant ability of IRF1 and inability of IRF8 to 
bind to the IL­12p40 promoter in cells treated with CT or 
dbcAMP prompted us to determine whether CT treatment 
Figure 5.  CT, but not CTB, blocks pDC differentiation in vitro and 
in vivo. (A–C) Bone marrow from BALB/c mice femurs was cultured in  
the presence of 100 ng/ml rh-FLT-3L with or without CT or CTB (both at 
20 ng/ml). Medium was changed at day 3 and 6 of culture and fresh  
FLT-3L and CT or CTB was added. After 9 d, cells were harvested and sub-
jected to flow cytometry to determine their phenotype. pDCs were defined 
as CD11c+CD11bB220+Ly6C+. (A) Untreated. (B) CT treated. (C) CTB treated. 
(D) Total spleen cells from mice injected with 5 µg of CT i.p. were  
harvested 48 h later. pDCs are identified as CD11c+CD19mPDCA-
1+Ly6C+ cells. Data shown is representative of four experiments  
yielding similar results.
 JEM VOL. 206, June 8, 2009  1233
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pDC differentiation (Fig. 5 C), indicating that this effect of 
CT is dependent on the CTA activity. Consistent with these 
results, and similar to our findings with CD8+ DCs, pDCs 
were preferentially lost after CT treatment in vivo (Fig. 5 D). 
The ability of CT to inhibit the differentiation of pDCs from 
FLT­3L–treated bone marrow and to induce pDC depletion 
in vivo is consistent with the hypothesis that IRF8–DNA inter­
action is a major target of CT activity.
In summary, our findings indicate that CT can inhibit 
IL­12 production in vivo after infection with T. gondii, or 
systemic administration of LPS. In addition, we identify the 
inhibition of IRF8 function as a major molecular mechanism 
by which CT and other cAMP­inducing agents prevent IL­12 
production in vitro and in vivo. Furthermore, we demonstrate 
that the CT­induced block of IRF8 function is associated with 
impaired IRF1–IRF8 heterocomplex formation that is inde­
pendent of the phosphorylation state of IRF1. Finally, by 
blocking IRF8 function, CT may simultaneously inhibit 
IL­12p40 mRNA expression in macrophages and differenti­
ated DCs and interfere with normal differentiation of CD8+ 
DCs (and pDCs) that represent a primary source of IL­12, at 
least under certain stimulation conditions.
MATERIALS AND METHODS
Mice and cell lines. 8–12­wk­old conventionally housed female BALB/c 
mice were obtained from the National Cancer Institute and were used as ap­
proved under animal study protocol LMI11E by the National Institute of 
Allergy and Infectious Disease/National Institutes of Health (NIH) Animal 
Care and Use Committee. The derivation and maintenance of IRF8/ 
Tot2 cells and their transfection with IRF8­GFP were previously described (30). 
The mouse macrophage cell line RAW 264.7 was purchased from American 
Type Culture Collection (ATCC).
Cell culture and measurement of cytokines. CD11c+ splenocytes were 
isolated using anti–mouse­CD11c immunomagnetic beads (Miltenyi Biotech). 
Human monocytes were obtained by counterflow centrifugation­elutriation 
of blood collected from normal blood donors under the NIH Institutional 
Review Board–approved human subjects protocol 99­cc­0168. Monocyte­
derived  DCs  were  obtained  by  culturing  purified  human  monocytes  in 
GMCSF and IL­4, as previously described (5). The mouse macrophage cell 
line RAW 264.7 was and stimulated at 80% confluence. CD11c+ spleno­
cytes, human blood monocytes, monocyte­derived DCs (Mo­DC), or the 
RAW 264.7 cells were cultured at 1–2 × 106 cells/ml in RPMI­1640 and 
supplemented with 10% FCS, 100 µg/ml penicillin, 100 µg/ml streptomy­
cin, 50 µg/ml gentamicin, 5% NCTC­109 media (all from Invitrogen),   
15 mM Hepes, and 200 mM glutamine (cRPMI) at 37°C and 5% CO2 with 
various stimuli as indicated. CT was purchased from List Biological Labora­
tories. Staphylococcus aureus, Cowan’s strain I (SAC; Pansorbin) was obtained 
from Calbiochem. Recombinant mouse IFN­ was obtained from BD. LPS 
(from Escherichia coli, serotype 0127:B8) and salbutamol were purchased from 
Sigma­Aldrich. Anti–mouse–IL­12 (clone C17.6) was originally provided 
by G. Trinchieri (National Cancer Institute, Bethesda, MD). CGS21680 and 
ZM241385 were obtained from Tocris Bioscience. Cytokine levels in cell 
culture supernatants and mouse sera were measured by ELISA using standard 
kits (BD). ELISA lower limit of detection was 50 pg/ml for IFN­ and IL­12 
p70 and 30 pg/ml for IL­12 p40.
T. gondii infection. T. gondii cysts (ME­49 strain) were prepared from brains 
of infected mice as previously described (31). BALB/c mice were untreated 
or treated with two doses of CT (5 µg) or anti–IL­12 antibody (1.8 mg) given 
could inhibit the formation of the IRF1–IRF8 heterocom­
plex. Consistent with this possibility, CT markedly reduced 
the amount of nuclear IRF1–IRF8 complex induced by LPS 
and IFN­ (Fig. 4 D). Tyrosine phosphorylation of IRF1 is a 
crucial event for IRF1–IRF8 complex formation (27). How­
ever, the amount of phosphorylated IRF1 induced by LPS 
and IFN­ was not modified by CT (Fig. 4 E). This indicates 
that the ability of CT to block IRF1–IRF8 complex forma­
tion is not caused by impaired IRF1 phosphorylation.
Together with IL­12 suppression, CT can enhance the 
ability of TLR ligands to induce DC production of IL­6, IL­1, 
and IL­10, while inhibiting their production of TNF­ (4). 
We confirmed the ability of CT and dbcAMP to inhibit the 
production of IL­12 and TNF­, but not IL­10, in human 
peripheral  blood  monocytes,  monocyte­derived  DCs,  and 
the RAW 264.7 cell line stimulated with LPS and IFN­ 
(Fig. S4). Interestingly, recent data indicate that TNF­ gene 
transcription in mouse macrophages is also regulated by IRF1 
and IRF8 (28). Therefore, it is feasible that the mechanism by 
which CT and cyclic AMP blocks TNF­ production is also 
caused by effects on IRF1–IRF8 interactions. The molecular 
events triggered by CT that lead to reduced IRF1–IRF8 inter­
action remain unclear. In addition to IRF1, IRF8 has been 
reported to form heterocomplexes with other binding part­
ners, including NFAT and PU.1. Interference with physical 
interaction between these proteins and IRF8 might regulate 
its ability to associate with DNA and IRF1. In support of this 
possibility, increased cAMP levels have been reported to in­
hibit NFAT activity (29). PKA­dependent phosphorylation 
of NFAT increased 14–3­3 binding and reduced NFAT tran­
scription activity at the IL­2 promotor. Whether CT and other 
cAMP inducers might affect such interactions is currently 
under investigation in our laboratories.
CT blocks the differentiation of pDCs from bone-marrow 
cells cultured with fms-related tyrosine kinase 3 ligand  
(FLT-3L) in vitro and mouse spleen cells in vivo
Results of the FRAP analysis indicate that CT induces a gen­
eral inhibition of IRF8 function, suggesting that other IRF8­
dependent processes might also be affected. IRF8 plays a key 
role not only in the activation of IL­12p35 and p40 genes, 
but also in the normal development of pDC and CD8+ 
cDC populations in vivo (18–21). Moreover, IRF8­deficent 
bone marrow cells fail to differentiate into pDCs when cul­
tured in the presence of FLT­3L in vitro (21). We therefore 
studied the effect of CT on the generation of pDCs from 
FLT­3L–stimulated bone marrow cultures. In keeping with 
previous reports, after culture with FLT­3L, one third of 
mouse  bone  marrow  cells  differentiated  into  CD11c+ 
CD11b cells that also expressed B220 and Ly6c and could 
therefore be identified as pDCs (Fig. 5 A). In the presence of 
CT, we observed a dramatic reduction of the CD11c+CD11b 
subset (from 34.6 to 4.28%), and a concomitant increase in the 
CD11c+CD11b+ population. In addition, only 50% of the re­
maining CD11c+CD11b cells expressed Ly6C (Fig. 5 B). 
Conversely, exposure to CTB did not alter FLT­3L–induced 1234 CT-INDUCED INHIBITION OF IRF8 FUNCTION | la Sala et al.
Bone marrow–derived pDCs. Bone marrow from 6­wk­old mice was 
cultured at 5 × 105 cells/ml in D­MEM (Biofluids, Inc.) supplemented with 
10% fetal bovine serum and containing 100 ng/ml recombinant human 
FLT­3L (PeproTech). Medium together with FLT­3L was changed at days 
3 and 6 of culture. CT or CTB was added at 20 ng/ml final concentration at 
the beginning of the culture and at every medium change. After 9 d, cells 
were analyzed by flow cytometry using fluorochrome­conjugated monoclo­
nal antibodies against CD11c, CD11b, B220, and Ly6C (BD).
Statistical analysis. Results represent the mean ± SD where applicable. 
Statistical significance of differences was determined by the Student’s t test.
Online supplemental material. Fig. S1 demonstrates the regulation of 
IL­12 production from murine cDCs by the 2 adrenergic agonist Salbuta­
mol, the adenosine A2a receptor agonist CGS21680, the adenosine A2a 
receptor antagonist ZM241385 and CT. Fig. S2 shows the time course of 
CD8+ cDC loss as well as annexin V staining of CD8+ cDCs after CT 
administration in vivo. Fig. S3 demonstrates the effect of CT dose on CD8+ 
DC loss, and the effect on IL­12 and IFN­ production in vivo. Fig. S4 
demonstrates the effect of CT and dbcAMP on IL­12, TNF­, and IL­10 
production from human monocytes, monocyte­derived DCs, and RAW 
264.7 cells. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20080192/DC1.
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